Sarepta (SRPT) Wins Key PTO Decision on Composition of Matter Patents - Oppenheimer
- Asian shares extend gains ahead of tech earnings, yen fragile
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil prices stabilise, Middle East tensions remain in focus
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
Sarepta Therapeutics Announces FDA Accelerated Approval of EXONDYS 51™ (eteplirsen) injection, an Exon Skipping Therapy to Treat Duchenne Muscular Dystrophy (DMD) Patients Amenable to Skipping Exon
September 19, 2016 1:39 PM EDT-- EXONDYS 51 the first DMD treatment approved in the US, targets dystrophin deficiency, the underlying cause of Duchenne --
--U.S. Commercial Launch planned to commence immediately--
--Conference call Scheduled for September 19, 2016, 4:00 p.m. EST--
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for EXONDYS 51 (eteplirsen) as a once weekly intravenous infusion of 30Â milligrams per kilogram for the treatment... More